Zimmer Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>ZB</div>
ZBH -- USA Stock  

USD 150.02  0.34  0.23%

Zimmer Biomet Average Assets are most likely to increase significantly in the upcoming years. The last year's value of Average Assets was reported at 22.1 Billion. The current Earnings before Tax is estimated to increase to about 142.2 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to roughly 1.7 B. Zimmer Biomet Holdings is scheduled to announce its earnings today. The next earnings report is expected on the 2nd of February 2021. As many risky investors are excited about healthcare space, it is only fair to concentrate on Zimmer Biomet Holdings based on its current volatility. I will address the reasons this entity was abused by stockholders resulted from the current market uncertainty. The company current probability of bankruptcy is under 40 percent. Will stockholders continue to be optimistic, or should we expect a sell-off?
Published over two weeks ago
View all stories for Zimmer Biomet | View All Stories
Are stockholders happy with Zimmer Biomet (NYSE:ZBH) technical and fundamental indicators?
Zimmer Biomet has performance score of 1 on a scale of 0 to 100. The firm maintains a market beta of 0.0883, which attests to not very significant fluctuations relative to the market. Let's try to break down what Zimmer's beta means in this case. As returns on the market increase, Zimmer Biomet returns are expected to increase less than the market. However, during the bear market, the loss on holding Zimmer Biomet will be expected to be smaller as well. Although it is extremely important to respect Zimmer Biomet Holdings historical price patterns, it is better to be realistic regarding the information on equity current price history. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By examining Zimmer Biomet Holdings technical indicators, you can presently evaluate if the expected return of 0.0221% will be sustainable into the future. Zimmer Biomet Holdings right now maintains a risk of 1.54%. Please check out Zimmer Biomet Holdings value at risk, as well as the relationship between the skewness and day median price to decide if Zimmer Biomet Holdings will be following its historical returns.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Zimmer Biomet income statement, its balance sheet, and the statement of cash flows. Potential Zimmer Biomet investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Zimmer Biomet investors may use each financial statement separately, they are all related. The changes in Zimmer Biomet's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zimmer Biomet's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Zimmer Biomet fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Zimmer Biomet performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Zimmer Biomet shares is the value that is considered the true value of the share. If the intrinsic value Zimmer is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Zimmer Biomet. Please read more on our fundamental analysis page.

What is Zimmer Asset Breakdown?

Zimmer Biomet Holdings reports assets on its Balance Sheet. It represents the amount of Zimmer resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Zimmer volatility, please check the breakdown of all its fundamentals

Are Zimmer Biomet Earnings Expected to grow?

The future earnings power of Zimmer Biomet involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Zimmer Biomet factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Zimmer Biomet stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Zimmer expected earnings.

And What about dividends?

A dividend is the distribution of a portion of Zimmer Biomet earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Zimmer Biomet dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Zimmer one year expected dividend income is about $0.56 per share.
The current Dividend Yield is estimated to increase to 0.0108, while Payment of Dividends and Other Cash Distributions is projected to decrease to (194.9 M).
Last ReportedProjected for 2020
Payment of Dividends and Other Cash Distributions-180.7 M-194.9 M
Dividend Yield 0.0103  0.0108 
Dividends per Basic Common Share 0.79  0.76 
Investing in dividend-paying stocks, such as Zimmer Biomet Holdings is one of the few strategies that are good for long-term investment. Ex-dividend dates are significant because investors in Zimmer Biomet must own a stock before its ex-dividend date to receive its next dividend. This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Zimmer Biomet. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Zimmer Biomet, but it might be worth checking our own buy vs. sell analysis

Zimmer Biomet Gross Profit

Zimmer Biomet Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Zimmer Biomet previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Zimmer Biomet Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Sale by Sang Yi of 1200 shares of Zimmer Biomet

Legal trades by Zimmer Biomet insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Zimmer insider trading alert for sale of common stock by Sang Yi, President Asia Pacific, on 20th of November 2020. This event was filed by Zimmer Biomet Holdings In with SEC on 2020-11-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Zimmer Biomet Investor Appetite?

There are few distinct groups of Zimmer Biomet stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Zimmer is distributed among investors.

Ownership Allocation

Zimmer Biomet Holdings retains a total of two hundred seven million fifty thousand outstanding shares. The majority of Zimmer Biomet outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zimmer Biomet Holdings to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zimmer Biomet Holdings. Please pay attention to any change in the institutional holdings of Zimmer Biomet Holdings as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.

Retail Investors
9.32%
Institutions
90.49%
Retail Investors9.32
Insiders0.19
Institutions90.49

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zimmer Biomet has an asset utilization ratio of 25.88 percent. This implies that the company is making $0.26 for each dollar of assets. An increasing asset utilization means that Zimmer Biomet Holdings is more efficient with each dollar of assets it utilizes for everyday operations.

Assets Non Current
20.7 B
Goodwill
18.1 B
Current Assets4.28 Billion9.89
Assets Non Current20.69 Billion47.8
Goodwill18.14 Billion41.91
Tax Assets173.1 Million0.4

Zimmer Biomet is projected to stay under $141 in December

Current kurtosis is at 0.57. Zimmer Biomet Holdings has relatively low volatility with skewness of 0.0 and kurtosis of 0.57. However, we advise all investors to independently investigate Zimmer Biomet Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

When is the right time to buy or sell Zimmer Biomet Holdings? Buying stocks such as Zimmer Biomet isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. With an optimistic outlook on your 30 days horizon, it may be a good time to purchase new shares of Zimmer or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Zimmer Biomet.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Zimmer Biomet Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com